Signaturefd LLC Has $1.94 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Signaturefd LLC grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 10.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 23,992 shares of the biopharmaceutical company’s stock after buying an additional 2,249 shares during the period. Signaturefd LLC’s holdings in Gilead Sciences were worth $1,944,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Lindbrook Capital LLC lifted its position in shares of Gilead Sciences by 37.0% in the fourth quarter. Lindbrook Capital LLC now owns 3,269 shares of the biopharmaceutical company’s stock worth $265,000 after buying an additional 883 shares during the last quarter. abrdn plc lifted its position in shares of Gilead Sciences by 89.0% during the 4th quarter. abrdn plc now owns 3,764,107 shares of the biopharmaceutical company’s stock worth $304,930,000 after purchasing an additional 1,772,887 shares during the last quarter. J.W. Cole Advisors Inc. lifted its position in shares of Gilead Sciences by 6.7% during the 4th quarter. J.W. Cole Advisors Inc. now owns 41,882 shares of the biopharmaceutical company’s stock worth $3,393,000 after purchasing an additional 2,638 shares during the last quarter. Wetzel Investment Advisors Inc. acquired a new position in shares of Gilead Sciences during the 4th quarter worth about $74,000. Finally, Greenleaf Trust lifted its position in shares of Gilead Sciences by 6.4% during the 4th quarter. Greenleaf Trust now owns 40,491 shares of the biopharmaceutical company’s stock worth $3,280,000 after purchasing an additional 2,429 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Royal Bank of Canada cut their price objective on Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating for the company in a research report on Wednesday, February 14th. Barclays cut their price objective on Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating for the company in a research report on Monday, February 12th. Cantor Fitzgerald cut their price objective on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a research report on Wednesday, February 7th. Wells Fargo & Company cut their price target on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a report on Monday, March 4th. Finally, Mizuho cut their price target on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a report on Thursday, February 22nd. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $84.71.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the sale, the insider now directly owns 96,304 shares in the company, valued at approximately $7,026,339.84. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Price Performance

Shares of GILD stock traded up $0.60 during trading hours on Friday, hitting $66.76. The company had a trading volume of 10,657,002 shares, compared to its average volume of 5,923,117. Gilead Sciences, Inc. has a 12 month low of $65.90 and a 12 month high of $87.86. The firm has a market capitalization of $83.12 billion, a price-to-earnings ratio of 14.84, a PEG ratio of 0.92 and a beta of 0.19. The firm’s fifty day moving average is $71.96 and its 200 day moving average is $76.56. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.76 by ($0.04). Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The company had revenue of $7.12 billion during the quarter, compared to the consensus estimate of $7.10 billion. During the same quarter in the prior year, the company posted $1.67 earnings per share. The company’s revenue for the quarter was down 3.7% on a year-over-year basis. On average, sell-side analysts predict that Gilead Sciences, Inc. will post 6.55 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Friday, March 15th were given a dividend of $0.77 per share. The ex-dividend date of this dividend was Thursday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.75. This represents a $3.08 dividend on an annualized basis and a yield of 4.61%. Gilead Sciences’s dividend payout ratio is 68.44%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.